List of Tables
Table 1. Global Sterile Injectable CDMO Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Sterile Injectable CDMO Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Sterile Injectable CDMO Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Sterile Injectable CDMO Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Sterile Injectable CDMO Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Sterile Injectable CDMO Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Sterile Injectable CDMO Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Sterile Injectable CDMO by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Sterile Injectable CDMO as of 2024)
Table 11. Global Sterile Injectable CDMO Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Sterile Injectable CDMO Companies Headquarters
Table 13. Global Sterile Injectable CDMO Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Sterile Injectable CDMO Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Sterile Injectable CDMO Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Sterile Injectable CDMO Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Sterile Injectable CDMO Revenue by Application (2026-2031) & (US$ Million)
Table 21. Sterile Injectable CDMO High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Sterile Injectable CDMO Growth Accelerators and Market Barriers
Table 25. North America Sterile Injectable CDMO Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Sterile Injectable CDMO Growth Accelerators and Market Barriers
Table 27. Europe Sterile Injectable CDMO Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Sterile Injectable CDMO Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Sterile Injectable CDMO Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Sterile Injectable CDMO Investment Opportunities and Key Challenges
Table 31. Central and South America Sterile Injectable CDMO Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Sterile Injectable CDMO Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Sterile Injectable CDMO Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Abbvie Corporation Information
Table 35. Abbvie Description and Major Businesses
Table 36. Abbvie Product Features and Attributes
Table 37. Abbvie Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Abbvie Revenue Proportion by Product in 2024
Table 39. Abbvie Revenue Proportion by Application in 2024
Table 40. Abbvie Revenue Proportion by Geographic Area in 2024
Table 41. Abbvie Sterile Injectable CDMO SWOT Analysis
Table 42. Abbvie Recent Developments
Table 43. Famar Corporation Information
Table 44. Famar Description and Major Businesses
Table 45. Famar Product Features and Attributes
Table 46. Famar Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Famar Revenue Proportion by Product in 2024
Table 48. Famar Revenue Proportion by Application in 2024
Table 49. Famar Revenue Proportion by Geographic Area in 2024
Table 50. Famar Sterile Injectable CDMO SWOT Analysis
Table 51. Famar Recent Developments
Table 52. Polfa Tarchomin Corporation Information
Table 53. Polfa Tarchomin Description and Major Businesses
Table 54. Polfa Tarchomin Product Features and Attributes
Table 55. Polfa Tarchomin Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Polfa Tarchomin Revenue Proportion by Product in 2024
Table 57. Polfa Tarchomin Revenue Proportion by Application in 2024
Table 58. Polfa Tarchomin Revenue Proportion by Geographic Area in 2024
Table 59. Polfa Tarchomin Sterile Injectable CDMO SWOT Analysis
Table 60. Polfa Tarchomin Recent Developments
Table 61. Pfizer Corporation Information
Table 62. Pfizer Description and Major Businesses
Table 63. Pfizer Product Features and Attributes
Table 64. Pfizer Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Pfizer Revenue Proportion by Product in 2024
Table 66. Pfizer Revenue Proportion by Application in 2024
Table 67. Pfizer Revenue Proportion by Geographic Area in 2024
Table 68. Pfizer Sterile Injectable CDMO SWOT Analysis
Table 69. Pfizer Recent Developments
Table 70. Quotient Sciences Corporation Information
Table 71. Quotient Sciences Description and Major Businesses
Table 72. Quotient Sciences Product Features and Attributes
Table 73. Quotient Sciences Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Quotient Sciences Revenue Proportion by Product in 2024
Table 75. Quotient Sciences Revenue Proportion by Application in 2024
Table 76. Quotient Sciences Revenue Proportion by Geographic Area in 2024
Table 77. Quotient Sciences Sterile Injectable CDMO SWOT Analysis
Table 78. Quotient Sciences Recent Developments
Table 79. Temad Co. Corporation Information
Table 80. Temad Co. Description and Major Businesses
Table 81. Temad Co. Product Features and Attributes
Table 82. Temad Co. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Temad Co. Recent Developments
Table 84. Tianjin Hankang Pharmaceutical Biotechnology Corporation Information
Table 85. Tianjin Hankang Pharmaceutical Biotechnology Description and Major Businesses
Table 86. Tianjin Hankang Pharmaceutical Biotechnology Product Features and Attributes
Table 87. Tianjin Hankang Pharmaceutical Biotechnology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Tianjin Hankang Pharmaceutical Biotechnology Recent Developments
Table 89. Fareva Corporation Information
Table 90. Fareva Description and Major Businesses
Table 91. Fareva Product Features and Attributes
Table 92. Fareva Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Fareva Recent Developments
Table 94. Sharp Corporation Information
Table 95. Sharp Description and Major Businesses
Table 96. Sharp Product Features and Attributes
Table 97. Sharp Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Sharp Recent Developments
Table 99. Astral SteriTech Corporation Information
Table 100. Astral SteriTech Description and Major Businesses
Table 101. Astral SteriTech Product Features and Attributes
Table 102. Astral SteriTech Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Astral SteriTech Recent Developments
Table 104. Evonik Corporation Information
Table 105. Evonik Description and Major Businesses
Table 106. Evonik Product Features and Attributes
Table 107. Evonik Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Evonik Recent Developments
Table 109. Aurigene Pharmaceutical Services Corporation Information
Table 110. Aurigene Pharmaceutical Services Description and Major Businesses
Table 111. Aurigene Pharmaceutical Services Product Features and Attributes
Table 112. Aurigene Pharmaceutical Services Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Aurigene Pharmaceutical Services Recent Developments
Table 114. Prague Scientific Corporation Information
Table 115. Prague Scientific Description and Major Businesses
Table 116. Prague Scientific Product Features and Attributes
Table 117. Prague Scientific Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. Prague Scientific Recent Developments
Table 119. Ethypharm Corporation Information
Table 120. Ethypharm Description and Major Businesses
Table 121. Ethypharm Product Features and Attributes
Table 122. Ethypharm Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. Ethypharm Recent Developments
Table 124. TriRx Pharmaceutical Services Corporation Information
Table 125. TriRx Pharmaceutical Services Description and Major Businesses
Table 126. TriRx Pharmaceutical Services Product Features and Attributes
Table 127. TriRx Pharmaceutical Services Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. TriRx Pharmaceutical Services Recent Developments
Table 129. Biophrama Group Corporation Information
Table 130. Biophrama Group Description and Major Businesses
Table 131. Biophrama Group Product Features and Attributes
Table 132. Biophrama Group Revenue (US$ Million) and Gross Margin (2020-2025)
Table 133. Biophrama Group Recent Developments
Table 134. Gensenta Pharmaceuticals Corporation Information
Table 135. Gensenta Pharmaceuticals Description and Major Businesses
Table 136. Gensenta Pharmaceuticals Product Features and Attributes
Table 137. Gensenta Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 138. Gensenta Pharmaceuticals Recent Developments
Table 139. BioTechnique Corporation Information
Table 140. BioTechnique Description and Major Businesses
Table 141. BioTechnique Product Features and Attributes
Table 142. BioTechnique Revenue (US$ Million) and Gross Margin (2020-2025)
Table 143. BioTechnique Recent Developments
Table 144. Mithra CDMo Corporation Information
Table 145. Mithra CDMo Description and Major Businesses
Table 146. Mithra CDMo Product Features and Attributes
Table 147. Mithra CDMo Revenue (US$ Million) and Gross Margin (2020-2025)
Table 148. Mithra CDMo Recent Developments
Table 149. S.C. Rompharm Company SRL Corporation Information
Table 150. S.C. Rompharm Company SRL Description and Major Businesses
Table 151. S.C. Rompharm Company SRL Product Features and Attributes
Table 152. S.C. Rompharm Company SRL Revenue (US$ Million) and Gross Margin (2020-2025)
Table 153. S.C. Rompharm Company SRL Recent Developments
Table 154. Flagship Biotech International Pvt. Ltd Corporation Information
Table 155. Flagship Biotech International Pvt. Ltd Description and Major Businesses
Table 156. Flagship Biotech International Pvt. Ltd Product Features and Attributes
Table 157. Flagship Biotech International Pvt. Ltd Revenue (US$ Million) and Gross Margin (2020-2025)
Table 158. Flagship Biotech International Pvt. Ltd Recent Developments
Table 159. Curida AS Corporation Information
Table 160. Curida AS Description and Major Businesses
Table 161. Curida AS Product Features and Attributes
Table 162. Curida AS Revenue (US$ Million) and Gross Margin (2020-2025)
Table 163. Curida AS Recent Developments
Table 164. BirgiMefar Group Corporation Information
Table 165. BirgiMefar Group Description and Major Businesses
Table 166. BirgiMefar Group Product Features and Attributes
Table 167. BirgiMefar Group Revenue (US$ Million) and Gross Margin (2020-2025)
Table 168. BirgiMefar Group Recent Developments
Table 169. Brooks Laboratories Limited Corporation Information
Table 170. Brooks Laboratories Limited Description and Major Businesses
Table 171. Brooks Laboratories Limited Product Features and Attributes
Table 172. Brooks Laboratories Limited Revenue (US$ Million) and Gross Margin (2020-2025)
Table 173. Brooks Laboratories Limited Recent Developments
Table 174. Raw Materials Key Suppliers
Table 175. Distributors List
Table 176. Market Trends and Market Evolution
Table 177. Market Drivers and Opportunities
Table 178. Market Challenges, Risks, and Restraints
Table 179. Research Programs/Design for This Report
Table 180. Key Data Information from Secondary Sources
Table 181. Key Data Information from Primary Sources
List of Figures
Figure 1. Sterile Injectable CDMO Product Picture
Figure 2. Global Sterile Injectable CDMO Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Preclinical Manufacturing Product Picture
Figure 4. Clinical Manufacturing Product Picture
Figure 5. Commercial Manufacturing Product Picture
Figure 6. Global Sterile Injectable CDMO Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Pharmaceutical Company
Figure 8. Research Institute
Figure 9. Other
Figure 10. Sterile Injectable CDMO Report Years Considered
Figure 11. Global Sterile Injectable CDMO Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Sterile Injectable CDMO Revenue (2020-2031) & (US$ Million)
Figure 13. Global Sterile Injectable CDMO Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global Sterile Injectable CDMO Revenue Market Share by Region (2020-2031)
Figure 15. Global Sterile Injectable CDMO Revenue Market Share Ranking (2024)
Figure 16. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 17. Preclinical Manufacturing Revenue Market Share by Player in 2024
Figure 18. Clinical Manufacturing Revenue Market Share by Player in 2024
Figure 19. Commercial Manufacturing Revenue Market Share by Player in 2024
Figure 20. Global Sterile Injectable CDMO Revenue Market Share by Type (2020-2031)
Figure 21. Global Sterile Injectable CDMO Revenue Market Share by Application (2020-2031)
Figure 22. North America Sterile Injectable CDMO Revenue YoY (2020-2031) & (US$ Million)
Figure 23. North America Top 5 Players Sterile Injectable CDMO Revenue (US$ Million) in 2024
Figure 24. North America Sterile Injectable CDMO Revenue (US$ Million) by Type (2020 - 2031)
Figure 25. North America Sterile Injectable CDMO Revenue (US$ Million) by Application (2020-2031)
Figure 26. US Sterile Injectable CDMO Revenue (2020-2031) & (US$ Million)
Figure 27. Canada Sterile Injectable CDMO Revenue (2020-2031) & (US$ Million)
Figure 28. Mexico Sterile Injectable CDMO Revenue (2020-2031) & (US$ Million)
Figure 29. Europe Sterile Injectable CDMO Revenue YoY (2020-2031) & (US$ Million)
Figure 30. Europe Top 5 Players Sterile Injectable CDMO Revenue (US$ Million) in 2024
Figure 31. Europe Sterile Injectable CDMO Revenue (US$ Million) by Type (2020-2031)
Figure 32. Europe Sterile Injectable CDMO Revenue (US$ Million) by Application (2020-2031)
Figure 33. Germany Sterile Injectable CDMO Revenue (2020-2031) & (US$ Million)
Figure 34. France Sterile Injectable CDMO Revenue (2020-2031) & (US$ Million)
Figure 35. U.K. Sterile Injectable CDMO Revenue (2020-2031) & (US$ Million)
Figure 36. Italy Sterile Injectable CDMO Revenue (2020-2031) & (US$ Million)
Figure 37. Russia Sterile Injectable CDMO Revenue (2020-2031) & (US$ Million)
Figure 38. Asia-Pacific Sterile Injectable CDMO Revenue YoY (2020-2031) & (US$ Million)
Figure 39. Asia-Pacific Top 8 Players Sterile Injectable CDMO Revenue (US$ Million) in 2024
Figure 40. Asia-Pacific Sterile Injectable CDMO Revenue (US$ Million) by Type (2020-2031)
Figure 41. Asia-Pacific Sterile Injectable CDMO Revenue (US$ Million) by Application (2020-2031)
Figure 42. Indonesia Sterile Injectable CDMO Revenue (2020-2031) & (US$ Million)
Figure 43. Japan Sterile Injectable CDMO Revenue (2020-2031) & (US$ Million)
Figure 44. South Korea Sterile Injectable CDMO Revenue (2020-2031) & (US$ Million)
Figure 45. Australia Sterile Injectable CDMO Revenue (2020-2031) & (US$ Million)
Figure 46. India Sterile Injectable CDMO Revenue (2020-2031) & (US$ Million)
Figure 47. Indonesia Sterile Injectable CDMO Revenue (2020-2031) & (US$ Million)
Figure 48. Vietnam Sterile Injectable CDMO Revenue (2020-2031) & (US$ Million)
Figure 49. Malaysia Sterile Injectable CDMO Revenue (2020-2031) & (US$ Million)
Figure 50. Philippines Sterile Injectable CDMO Revenue (2020-2031) & (US$ Million)
Figure 51. Singapore Sterile Injectable CDMO Revenue (2020-2031) & (US$ Million)
Figure 52. Central and South America Sterile Injectable CDMO Revenue YoY (2020-2031) & (US$ Million)
Figure 53. Central and South America Top 5 Players Sterile Injectable CDMO Revenue (US$ Million) in 2024
Figure 54. Central and South America Sterile Injectable CDMO Revenue (US$ Million) by Type (2020-2031)
Figure 55. Central and South America Sterile Injectable CDMO Revenue (US$ Million) by Application (2020-2031)
Figure 56. Brazil Sterile Injectable CDMO Revenue (2020-2025) & (US$ Million)
Figure 57. Argentina Sterile Injectable CDMO Revenue (2020-2025) & (US$ Million)
Figure 58. Middle East and Africa Sterile Injectable CDMO Revenue YoY (2020-2031) & (US$ Million)
Figure 59. Middle East and Africa Top 5 Players Sterile Injectable CDMO Revenue (US$ Million) in 2024
Figure 60. South America Sterile Injectable CDMO Revenue (US$ Million) by Type (2020-2031)
Figure 61. Middle East and Africa Sterile Injectable CDMO Revenue (US$ Million) by Application (2020-2031)
Figure 62. GCC Countries Sterile Injectable CDMO Revenue (2020-2025) & (US$ Million)
Figure 63. Israel Sterile Injectable CDMO Revenue (2020-2025) & (US$ Million)
Figure 64. Egypt Sterile Injectable CDMO Revenue (2020-2025) & (US$ Million)
Figure 65. South Africa Sterile Injectable CDMO Revenue (2020-2025) & (US$ Million)
Figure 66. Sterile Injectable CDMO Industry Chain Mapping
Figure 67. Channels of Distribution (Direct Vs Distribution)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
